StockTipsArenaBeta

BUY Aarti Pharmalabs Limited — Nirav Chheda, Nirmal Bang Securities

BUYAarti Pharmalabs Limited
Aarti Pharmalabs share price target & all analyst calls

byNirav Chheda, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))9 Nov 2026via Zee Business (Live)

Entry₹925.35Inferred
Target₹1,100
Total upside +18.87%
Stop loss₹890-3.82% risk
CMP₹997.951d ago
Active+7.85%+10.23%upside left 8d left
Follow Nirav Chheda for new calls(19% target hit, 103 closed calls)Get alertsWatch AARTIPHARM for new buy/sell callsGet alertsSee 281 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:34 am IST
7 supporting2 neutral1 opposing
Supports the BUY call (7)

MACD above its signal line — bullish momentum

Technicals · macd·14 Nov · today

Aarti Pharmalabs Limited: 10-12 projects drive Rs 800 crore CDMO

NewsGoogle News·5 Nov · 1w ago

(opens in new tab)

Aarti Pharmalabs Limited Q2 Revenue Reaches Record Rs 613 Crore

NewsGoogle News·4 Nov · 1w ago

(opens in new tab)

Aarti Pharmalabs Q2 FY27 slides: revenue surges 47% on capacity ramp By Investing.com

NewsGoogle News·29 Oct · 2w ago

(opens in new tab)

Earnings call transcript: Aarti Pharmalabs Q2 2026 revenue jumps 47% as stock rises By Investing.com

NewsGoogle News·29 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Appointment of Smt. Vibha Thakkar as the new Chief Financial Officer.

NSE · Appointment·28 Oct · 2w ago

(opens in new tab)

Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·28 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 76 — overbought territory

Technicals · rsi·14 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aarti Pharmalabs

All analyst calls on Aarti Pharmalabs

More from Nirav Chheda, Nirmal Bang Securities

Every call and its outcome